A preliminary clinical investigation of a new MAO inhibiting antidepressant, phenoxypropazine, is reported. Of 20 cases, 14 were improved, and in 12 cases the response was highly satisfactory after 6 weeks. Side effects were comparatively few, and with one exception, mild. Hypotensive activity was slight.Abstract Teaser